Q2 2025 Medicover AB Earnings Call Transcript
Key Points
- Medicover AB (FRA:5M0B) reported a strong Q2 2025 with a 17.1% revenue growth, primarily driven by organic growth.
- The company achieved a significant profit margin expansion, with EBIT up 96% year-on-year and net profit tripling.
- Strong performance in the Polish market and maturing Romanian hospitals contributed positively to the results.
- The Ukrainian business showed improvement, benefiting from earlier initiatives.
- Diagnostics division experienced growing momentum, particularly in the Fee-for-Service segment, enhancing profitability.
- The German market faced challenges due to pricing reforms, requiring ongoing efficiency initiatives.
- Subdued member growth was noted, attributed to political uncertainties and delays in EU fund deployment.
- India's growth was initially subdued due to operational issues and external factors like elections and medical tourism visa delays.
- Leverage remained high at 3.6 times, though expected to decrease by year-end.
- New hospital openings, such as the 300-bed facility in India, may initially contribute to EBITDA losses due to immaturity.
Welcome to the Medicover Q2 2025 report presentation. (Operator Instructions)
Now I will hand the conference over to the speakers, CEO, John Stubbington; and CFO, Anand Patel. Please go ahead.
Good morning, everybody. It's John here, and welcome to our presentation for Q2. As you can see here on the headline, we've sort of positioned this as sustained high growth with strengthening profit margins, which I think is really, really good. When asked to frame the first quarter, from many people, I think I positioned it as strong. I think to frame the second quarter, our positioning would be -- actually, it's a little bit stronger.
You can see strong growth coming through with good operational leverage. And this, of course, is improving our operating cash flow, which we're very, very pleased with. From a growth perspective, 17.1%. We're seeing growth in all markets, which is good. A little bit later on, we'll talk you through each of the markets and how it's progressing. But literally across
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
